Novavax (NASDAQ: NVAX) reported Q2 EPS of $0.58, $2.10 better than the analyst estimate of ($1.52). Revenue for the quarter came in at $424.43 million versus the consensus estimate of $237.39 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.